Skip to content
ppharmaranks
Menu
Class IIOngoing

Nelarabine Injection recall

FDA recall D-0256-2025 · initiated Feb 13, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Mar 12, 2025How we research

Zydus Pharmaceuticals (USA) Inc recalled Nelarabine Injection in Feb 2025 — an FDA Class II recall (D-0256-2025) because Failed Impurities/Degradation Specifications.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Failed Impurities/Degradation Specifications

An impurity above the accepted limit

A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot: a) P300197, Exp. Aug-2025; P400113, Exp. May-26; b) P300169, Exp. Jun-2025; P400115, Exp. May-2026.

Quantity recalled: 1,893 vials

Details

Product
Nelarabine Injection, 250mg/50mL, (5mg/mL), packaged in: a) 50 mL Single-Dose Vial, NDC 70710-1839-1; b) 6 x 50 mL Single-Dose Vial, NDC 70710-1839-8, Rx only, Manufactured by Zydus Lifesciences Ltd, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc, Pennington, NJ
Recalling company
Zydus Pharms
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
USA Nationwide
Initiated
Feb 13, 2025
FDA report date
Mar 12, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Nelarabine Injection recalled?
Zydus Pharmaceuticals (USA) Inc recalled Nelarabine Injection in Feb 2025 — an FDA Class II recall (D-0256-2025) because Failed Impurities/Degradation Specifications. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Nelarabine Injection recalled?
Per the FDA enforcement record, the reason for recall D-0256-2025 was: Failed Impurities/Degradation Specifications
Is a recalled Nelarabine Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Nelarabine Injection are affected?
Distributed: USA Nationwide. The recall covers these lots — Lot: a) P300197, Exp. Aug-2025; P400113, Exp. May-26; b) P300169, Exp. Jun-2025; P400115, Exp. May-2026.. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0256-2025.

Source: openFDA Drug Enforcement record D-0256-2025

← All drug recalls